CCO
0.003
50%
AOK
0.002
-33.3%
M2R
0.003
50%
CAN
0.003
-25%
SPX
0.003
50%
KTA
0.004
-20%
TOU
0.003
50%
VIT
0.021
-19.2%
UM1
0.175
45.8%
ENL
0.005
-16.7%
AVE
0.02
33.3%
FEL
0.005
-16.7%
BLU
0.004
33.3%
HCL
0.096
-16.5%
HIQ
0.008
33.3%
BNL
0.006
-14.3%
EV8
0.575
25%
FIN
0.006
-14.3%
MGU
0.005
25%
KM1
0.09
-14.3%
LKO
0.63
23.5%
LIS
0.12
-14.3%
SIX
0.083
18.6%
PET
0.006
-14.3%
ZNO
0.059
18%
BAK
0.16
-13.5%
PKY
0.06
17.6%
AAU
0.007
-12.5%
BNZ
2.49
17.5%
MQR
0.007
-12.5%
SIS
0.007
16.7%
WOA
0.007
-12.5%
YAR
0.007
16.7%
TAS
0.053
-11.7%
CMO
0.008
14.3%
GED
0.038
-11.6%
MEL
0.016
14.3%
CRD
0.425
-11.5%
PV1
0.008
14.3%
WCN
0.016
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts